UBS lowered the firm’s price target on Biogen (BIIB) to $346 from $347 and keeps a Buy rating on the shares. Biogen posted a top and bottom-line beat in Q1, and the quarter provided "minimal" incremental updates of note, the analyst tells investors in a research note. The firm remains bullish on Biogen, and likes the risk-reward into Eli Lilly’s (LLY) Phase 3 data for donanemab expected in Q2, the full Leqembi approval and reimbursement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen price target raised to $325 from $310 at Oppenheimer
- Biogen price target lowered to $302 from $307 at Barclays
- FDA approves Ionis Pharma/Biogen’s QALSODY as first treatment in ALS
- Biogen price target raised to $371 from $349 at Morgan Stanley
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS